Literature DB >> 6168696

Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes.

P Hokland, K Berg.   

Abstract

Polymorphonuclear leukocytes (PMN) from healthy volunteers were tested for ADCC activity against both erythrocyte and tumor targets with and without the addition of human leukocyte interferon (IFN). It was demonstrated that IFN within 30 to 60 min enhanced the reaction in a dose-dependent manner with minimal IFN doses ranging from 1 to 100 units. Formal proof that the augmenting agent was IFN was obtained by using pure IFN proteins in combination with both mock-IFN preparations, which showed no enhancing activity, and anti-IFN antisera, which inhibited the action of the completely purified IFN proteins. In the light of data demonstrating that the IFN effect was most pronounced when the IgG antibodies in the ADCC reaction were present in suboptimal amounts, it is hypothesized that IFN may play a special role in the early nonspecific immune response against non-self antigens.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168696

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

Authors:  G De Sanctis; V Bottari; A Frezzolini; M Ficcardi; G De Rossi; M C Petti; F Mandelli; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Modulation of granulocyte oxidative response by recombinant interferon alpha 2 and gamma.

Authors:  A Kapp; H Kirchner; H Wokalek; E Schöpf
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

3.  Antibody-mediated erythrolysis and erythrophagocytosis by human monocytes, macrophages and activated macrophages. Evidence for distinction between involvement of high-affinity and low-affinity receptors for IgG by using different erythroid target cells.

Authors:  S J Rüegg; T W Jungi
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

4.  Biosynthetic human interferon treatment of herpetic keratitis.

Authors:  G Smolin
Journal:  Trans Am Ophthalmol Soc       Date:  1983

5.  Divergence in activation by poly I:C of human natural killer and killer cells.

Authors:  B S Edwards; E C Borden; K Smith-Zaremba
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Stimulation of neutrophil respiratory burst and lysosomal enzyme release by human interferon-gamma.

Authors:  I C Kowanko; A Ferrante
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

7.  (2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections.

Authors:  A Schattner; G Merlin; V Bregman; T Hahn; S Levin; M Revel; D Wallach
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

8.  Human neutrophils require activation by mononuclear leucocyte conditioned medium to kill the pathogenic free-living amoeba, Naegleria fowleri.

Authors:  A Ferrante; T J Mocatta
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

9.  Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts.

Authors:  T Ihara; S E Starr; M Ito; S D Douglas; A M Arbeter
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

10.  Human polymorphonuclear neutrophil functions are unaffected by human interferon-alpha 2.

Authors:  B Farr; J M Gwaltney; F G Hayden; G L Mandell
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.